Angela R Corrigan, Shin Foong Ngiow, Maura Statzu, Amie Albertus, M Betina Pampena, Jayme M L Nordin, Stephen D Carro, Justin Harper, Rachelle L Stammen, Jennifer Wood, Houping Ni, Justin Su, Marziyeh Hajialyani, Vladimir V Shuvaev, Victor Alcalde, Mohammed-Alkhatim A Ali, Jacob T Hamilton, Rajesvaran Ramalingam, Vincent H Wu, Mirko Paiardini, Drew Weissman, E John Wherry, Edward F Kreider, Michael R Betts
{"title":"In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs.","authors":"Angela R Corrigan, Shin Foong Ngiow, Maura Statzu, Amie Albertus, M Betina Pampena, Jayme M L Nordin, Stephen D Carro, Justin Harper, Rachelle L Stammen, Jennifer Wood, Houping Ni, Justin Su, Marziyeh Hajialyani, Vladimir V Shuvaev, Victor Alcalde, Mohammed-Alkhatim A Ali, Jacob T Hamilton, Rajesvaran Ramalingam, Vincent H Wu, Mirko Paiardini, Drew Weissman, E John Wherry, Edward F Kreider, Michael R Betts","doi":"10.1126/sciimmunol.aec3436","DOIUrl":null,"url":null,"abstract":"<p><p>Selective in vivo reprogramming of cytotoxic effector CD8 T (T<sub>eff</sub>) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNPs) can specifically target and deliver mRNA to CX3CR1<sup>+</sup> T<sub>eff</sub> cells in vitro and in vivo. In mice, fractalkine-conjugated mRNA-LNPs targeted up to 95% of blood and splenic T<sub>eff</sub> cells. In addition, delivery of IL-2-encoding mRNA and human CD62L-encoding mRNA to mouse T<sub>eff</sub> cells enabled robust exogenous IL-2 secretion and CD62L expression. In rhesus macaques, fractalkine-conjugated mRNA-LNPs targeted up to ~100% of peripheral blood T<sub>eff</sub> cells, and delivery of human CD62L-encoding mRNA enabled cell-surface human CD62L expression on peripheral blood T<sub>eff</sub> cells and detection of human CD62L<sup>+</sup> T<sub>eff</sub> cells in lymphoid tissue. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNPs for rapid, efficient, and transient in vivo modification of T<sub>eff</sub> cells.</p>","PeriodicalId":21734,"journal":{"name":"Science Immunology","volume":"11 119","pages":"eaec3436"},"PeriodicalIF":16.3000,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1126/sciimmunol.aec3436","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Selective in vivo reprogramming of cytotoxic effector CD8 T (Teff) cells holds tremendous promise as a therapeutic tool but has not yet been accomplished. Here, we demonstrate that fractalkine-conjugated mRNA lipid nanoparticles (mRNA-LNPs) can specifically target and deliver mRNA to CX3CR1+ Teff cells in vitro and in vivo. In mice, fractalkine-conjugated mRNA-LNPs targeted up to 95% of blood and splenic Teff cells. In addition, delivery of IL-2-encoding mRNA and human CD62L-encoding mRNA to mouse Teff cells enabled robust exogenous IL-2 secretion and CD62L expression. In rhesus macaques, fractalkine-conjugated mRNA-LNPs targeted up to ~100% of peripheral blood Teff cells, and delivery of human CD62L-encoding mRNA enabled cell-surface human CD62L expression on peripheral blood Teff cells and detection of human CD62L+ Teff cells in lymphoid tissue. Collectively, these data demonstrate the potential of natural receptor ligand-based targeting of mRNA-LNPs for rapid, efficient, and transient in vivo modification of Teff cells.
期刊介绍:
Science Immunology is a peer-reviewed journal that publishes original research articles in the field of immunology. The journal encourages the submission of research findings from all areas of immunology, including studies on innate and adaptive immunity, immune cell development and differentiation, immunogenomics, systems immunology, structural immunology, antigen presentation, immunometabolism, and mucosal immunology. Additionally, the journal covers research on immune contributions to health and disease, such as host defense, inflammation, cancer immunology, autoimmunity, allergy, transplantation, and immunodeficiency. Science Immunology maintains the same high-quality standard as other journals in the Science family and aims to facilitate understanding of the immune system by showcasing innovative advances in immunology research from all organisms and model systems, including humans.